Division of Hematology/Oncology

Faculty

faculty photo

Nevena Damjanov, MD

Associate Professor of Clinical Medicine
Attending Physician, Hospital of the University of Pennsylvania
Attending Physician,, Penn Presbyterian Medical Center
Director of GI Oncology, Abramson Cancer Center at the Penn Presbyterian Medical Center
Director, Clinical Research Program, Abramson Cancer Center at the Penn Presbyterian Medical Center
Department: Medicine

Contact information
Penn Presbyterian Medical Center
51 North 39th Street
103A MAB
Philadelphia, PA 19104
Office: 215-662-9154
Fax: 215-243-3249
Education:
BA (Biology, Philosophy)
University of Pennsylvania, 1985.
MD (Internal Medicine)
Hahnemann University, 1989.
Post-Graduate Training
Residency in Internal Medicine, M.S. Hershey Medical Center, 1989-1992.
Fellowship in Hematology/Oncology, University of Pennsylvania Medical Center, 1992-1996.
Certifications
American Board of Internal Medicine (Internal Medicine), 1992.
American Board of Internal Medicine (Medical Oncology), 1995.
American Board of Internal Medicine (Hematology), 1996.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Sun, W., Sohal, D., Mykulowycz, K., Teitelbaum, U.R., Damjanov, N., Giantonio, B.J., Carberry, M., Wissel, P., Jacobs-Small, M., O’Dwyer, P.J.: An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. Journal of Clinical Oncology 30(328a), June 2012 Notes: Poster presentation and abstract.

Sinha S, Levine M, Damjanov N, Reddy KR, Olthoff K, Shaked A, Hoteit M: Hepato-Cholangiocarcinoma in Liver Transplantation: Frequency and Outcomes. American Journal of Transplantation 11 Suppl 2: 466-466, APR 2011 Notes: Meeting Abstract: 1501 (Poster presentation).

Hall, MJ, Egleston, B, Miller, SM, Buzaglo, JS, Millard, J, Ridgway, C, Damjanov, N, Sprandio, JD, Meropol, NJ: Barriers to participation in cancer prevention clinical trials. Acta Oncologica 49(6): 757-766, AUG 2010.

Ross, HJ, Blumenschein, GR, Aisner, J, Damjanov, N, Dowlati, A, Garst, J, Rigas, JR, Smylie, M, Hassani, H, Allen, KE, Leopold, L, Zaks, TZ, Shepherd, FA: Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research 16(6): 1938-1949, MAR 15 2010.

Sun W, Mykulowycz K, Teitelbaum UR, Damjanov N, Haller DG, Giantonio BJ, Carberry M, O’Dwyer PJ: Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study. Journal of Clinical Oncology 28(15s): suppl; abstr TPS214, 2010 Notes: Poster presentation

Damjanov N: Gastric Cancer. Core Content Review of Family Medicine 40(3): 57-59, 2009.

Damjanov, N, Weiss, J, Haller, DG: Resection of the Primary Colorectal Cancer Is Not Necessary in Nonobstructed Patients with Metastatic Disease. Oncologist 14(10): 963-969, 2009.

Damjanov, N: Commentary: Colonoscopic Findings and Tumor Site Do Not Predict Bowel Obstruction During Medical Treatment of Stage IV Colon Cancer. Oncologist 14(6): 578-579, 2009.

Fetterly, GJ, Grasela, TH, Sherman, JW, Dul, JL, Grahn, A, Lecomte, D, Fiedler-Kelly, J, Damjanov, N, Fishman, M, Kane, MP, Rubin, EH, Tan, AR: Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clinical Cancer Research 14(18): 5856-5863, SEP 15 2008.

Grasela TH, Fetterly GJ, Dul JL, LeComte D, Grahn AY, Fiedler-Kelly JB, Sherman JW, Damjanov N, Fishman MN, Tan AR: Modeling and simulation of neutropenia to support dosing regimens for liposome-encapsulated paclitaxel easy-to-use (LEP- ETU). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25(18S): 13011, JUN 20 Suppl 2007 Notes: Abstract only.

back to top
Last updated: 11/20/2014
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter